Welcome to our dedicated page for Protagonist Ther news (Ticker: PTGX), a resource for investors and traders seeking the latest updates and insights on Protagonist Ther stock.
Protagonist Therapeutics (PTGX) is a clinical-stage biopharmaceutical leader developing oral peptide therapies for inflammatory and hematologic conditions. This news hub provides investors and researchers with essential updates on clinical trials, regulatory milestones, and strategic partnerships.
Access timely announcements about PTGX's innovative constrained peptide platform and pipeline candidates like icotrokinra (IL-23 antagonist) and rusfertide (hepcidin mimetic). Our curated collection includes press releases on trial results, FDA communications, and collaborations with industry leaders including Johnson & Johnson.
Key updates cover therapeutic advancements for psoriasis, ulcerative colitis, and polycythemia vera. Bookmark this page to monitor Protagonist's progress in transforming biologic-like treatments into oral formulations while maintaining competitive positioning through proprietary drug discovery methods.
Protagonist Therapeutics (PTGX) has initiated a Phase 2b clinical trial for PN-235, an oral IL-23 receptor antagonist targeting moderate-to-severe plaque psoriasis, with a planned enrollment of 240 patients. The trial commenced on February 3, 2022. The company also announced a $25 million milestone payment from Janssen Biotech for the dosing of the third patient in this trial. Protagonist is eligible for up to $850 million in development-related milestone payments from Janssen, which will oversee all future clinical studies.
Protagonist Therapeutics (PTGX) reported its fourth-quarter and full-year 2021 financial results, highlighting a net loss of $36.9 million in Q4 and $125.6 million for the year. The company emphasized significant progress in its pipeline, particularly with rusfertide entering a Phase 3 study for polycythemia vera and PN-943 completing enrollment for its Phase 2 study in ulcerative colitis. License and collaboration revenue rose to $8.6 million in Q4, up from $5.7 million in the previous year, driven by collaboration with Janssen. Cash reserves of $326.9 million are expected to support operations through 2024.
Protagonist Therapeutics (Nasdaq: PTGX) will be presenting at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022, at 3:00 p.m. EST. The presentation by CEO Dinesh V. Patel will be available via live and archived webcast on their official website.
The company is advancing multiple clinical trials, including the REVIVE Phase 2 trial for rusfertide, aimed at treating polycythemia vera, and IDEAL Phase 2 study for PN-943 in ulcerative colitis.
Protagonist Therapeutics (Nasdaq: PTGX) announced a virtual presentation by Dr. Dinesh V. Patel at the J.P. Morgan Healthcare Conference on January 11, 2022, at 2:15 a.m. EST. Dr. Patel will also participate in a fireside chat at the H.C. Wainwright BioConnect 2022 Conference from January 10-13, 2022. Both events will be accessible via the company's Investors website. Protagonist is advancing multiple peptide-based therapies, including rusfertide (PTG-300) for polycythemia vera and PN-943 for ulcerative colitis, along with collaboration on PN-235 with Janssen Biotech.
Protagonist Therapeutics (PTGX) presented promising data from two ongoing Phase 2 studies of rusfertide for polycythemia vera (PV) at the ASH 2021 Annual Meeting. Results show that 84% of patients eliminated the need for phlebotomy, with rapid hematocrit control observed. The Phase 3 trial is set to begin in early 2022.
Notably, the drug was well tolerated, with minimal severe adverse events reported. Rusfertide may also have implications in treating hereditary hemochromatosis.
Protagonist Therapeutics (Nasdaq: PTGX) has announced that Dinesh V. Patel, CEO, will present at the JMP Securities Hematology and Oncology Summit on December 6, 2021, at 1:40 p.m. EST. A webcast will be available for 90 days on the company’s Investors website. Protagonist focuses on peptide-based therapeutics, including rusfertide (PTG-300) for polycythemia vera and PN-943 for ulcerative colitis. They also collaborate with Janssen Biotech on oral IL-23 receptor antagonists. This upcoming presentation marks a key moment for stakeholders and potential investors.
Protagonist Therapeutics (Nasdaq: PTGX) announced PN-235 as its main candidate for clinical studies, focusing on the IL-23 pathway, following a collaboration with Janssen. The Phase 2 study for psoriasis is set to begin in early 2022, along with new studies for inflammatory bowel diseases expected later. Protagonist will earn $25 million for the psoriasis study and is eligible for $900 million in future milestones. The company will discontinue PN-232 in favor of PN-235 due to its superior profile.
Protagonist Therapeutics (PTGX) announced promising results from a Phase 2a study for rusfertide, aimed at treating hereditary hemochromatosis (HH), a genetic disorder causing excessive iron absorption. The study involved 16 patients and demonstrated significant reductions in therapeutic phlebotomy requirements and improved serum iron levels. Rusfertide exhibited a favorable safety profile, with most adverse events being mild. This marks a critical step towards developing the first-in-class therapy for HH, addressing unmet medical needs for patients unable to undergo traditional phlebotomy.
Protagonist Therapeutics (Nasdaq: PTGX) announced that CEO Dinesh V. Patel, Ph.D., will present and engage in one-on-one investor meetings at the Jefferies London Healthcare Conference on November 18, 2021, and the Piper Sandler 33rd Annual Healthcare Conference on November 22, 2021. The Jefferies event is scheduled for 3 a.m. EST, while the Piper Sandler event will begin at 10 a.m. EST. A webcast will be available for 90 days on Protagonist's website. The company focuses on peptide-based therapies, including treatments for conditions like polycythemia vera and ulcerative colitis.
FAQ
What is the current stock price of Protagonist Ther (PTGX)?
What is the market cap of Protagonist Ther (PTGX)?
